- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undiscovered Gems With Strong Fundamentals
U.S. Pharmaceuticals & Biotech Undiscovered Gems With Strong Fundamentals
Results
6
High-performing small cap companies that haven't yet garnered significant analyst attention, and could lead to superior returns.
6 companies
Elite Pharmaceuticals
Market Cap: US$558.6m
A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.
ELTP
US$0.52
7D
-1.7%
1Y
-13.4%
OpGen
Market Cap: US$100.7m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
OPGN
US$10.50
7D
40.0%
1Y
650.0%
Puma Biotechnology
Market Cap: US$266.6m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.30
7D
5.0%
1Y
69.9%
SIGA Technologies
Market Cap: US$454.0m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.20
7D
2.3%
1Y
-10.9%
Oramed Pharmaceuticals
Market Cap: US$108.3m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$2.69
7D
-5.6%
1Y
12.1%
Gyre Therapeutics
Market Cap: US$718.0m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.98
7D
3.0%
1Y
-30.7%